Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q3 FY2020 Earnings Presentation
22 slides from Jubilant Pharmova's earnings presentation, Jan 31, 2020
Slide 1: Financial Results Quarter Ended Dec 31, 2019
Financial Results Quarter Ended Dec 31, 2019
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : January 31, 2020 Time : 05:00 pm IST Replay from : January 31 to February 08, 2020 Dial in No.: +91 22 7194 5757 Playback ID: 57866# 22
Slide 4: Chairmen's Message
Chairmen’s Message JUBILANT Q3’FY20 PERFORMANCE Revenue at Rs. 2,315 Crore lower by 3% YoY; EBITDA at Rs 513 Crore lower by 2% YoY and higher by 7% QoQ Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Scienc
Slide 5: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, the Company has filed with BSE Limited and National Stock Exchange of India Limited the Composite Scheme of Arrangement for amalgamation of certain promoter controlled entities
Slide 6: Q3'FY20 Results Analysis
wW Mirescncts Q3’FY20 Results Analysis
Slide 7: JLL – Q3'FY20 Financial Highlights
JLL – Q3’FY20 Financial Highlights YoY 1 Particulars Q3'FY19 Q3'FY20 Change (%) Revenue at Rs 2,315 Crore, a decrease of 3% YoY and an increase of 2% QoQ Revenue • Pharmaceuticals revenue at Rs 1,450 Crore, an increase of 2% YoY, contributing 63% Pharmaceuticals2 1,424 1,450 2% to revenue Life Sci
Slide 8: Pharmaceuticals Segment Highlights – Q3'FY20 (1/2)
Pharmaceuticals Segment Highlights – Q3’FY20 (1/2) Particulars1 Q3'FY19 Q3'FY20 % Change Pharmaceuticals revenue at Rs 1,450 Crore, an increase of 2% YoY. Revenue 1,424 1,450 2% Specialty Pharma and CDMO segments increased by 1% YoY and 5% YoY, Specialty Pharma 757 764 1% respectively. Generics
Slide 9: Pharmaceuticals Segment Highlights – Q3'FY20 (2/2)
Pharmaceuticals Segment Highlights – Q3’FY20 (2/2) USFDA Inspection Details Generics1 Facility Last Inspection • Revenue was flat YoY and down 2% QoQ primarily due to lower volumes in some key products due to customer scheduling Montreal, CMO May, 2018 Montreal, Radiopharma Sep, 2017 • Better pricin
Slide 10: LSI Segment Highlights – Q3'FY20
LSI Segment Highlights – Q3’FY20 Particulars 1 Q3'FY19 Q3'FY20 % Change LSI revenue at Rs 797 Crore, decreased by 11% YoY and increased by Revenue 899 797 (11%) 6% QoQ. Strong growth witnessed in Specialty Intermediates and Specialty Intermediates 252 293 16% Nutritional Products amid lower revenu
Slide 11: Drug Discovery & Development Solutions – Q3'FY20
Drug Discovery & Development Solutions – Q3’FY20 1 Particulars Q3'FY19 Q3'FY20 % Change Revenue 54 68 26% Drug Discovery & Development Solutions (DDDS) comprises Drug Discovery Services 54 68 26% • Drug Discovery Services business through Jubilant Biosys Proprietary Drug Discovery 0 0 - Limited &
Slide 12: Proprietary Drug Discovery (Jubilant Therapeutics)
Proprietary Drug Discovery (Jubilant Therapeutics) Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure-based design and computational architecture to disc
Slide 13: 9M'FY20 Results Analysis
9M’FY20 Results Analysis 12 12
Slide 14: JLL – 9M'FY20 Financial Highlights
JLL – 9M’FY20 Financial Highlights YoY Particulars1 9M'FY19 9M'FY20 Change (%) Revenue at Rs 6,763 Crore, increase of 1% from Rs 6,725 Crore in 9M’FY19 Revenue • Pharmaceuticals revenue at Rs 4,231 Crore, increased by 7% YoY, Pharmaceuticals2 3,943 4,231 7% contributing 62% to revenue Life Science
Slide 15: Adjusted Earnings
Adjusted Earnings Rs Crore Consol EBITDA % Change % Change S. No. Particulars Q3'FY19 Q3'FY20 YoY 9M'FY19 9M'FY20 YoY 1 Reported EBITDA 522 513 (2%) 1,423 1,438 1% 2 One-off Adjustments (5) 3 8 74 3 Adjusted EBITDA 518 516 (0%) 1,432 1,512 6% 4 Reported EBITDA Margin 22.0% 22.2% 21.2% 21.3% 5 Adjust
Slide 16: Pharmaceuticals Segment Highlights – 9M'FY20
Pharmaceuticals Segment Highlights – 9M’FY20 Particulars1 9M'FY19 9M'FY20 % Change Geography Wise Revenue1 Revenue 3,943 4,231 7% 3,211 3,495 Specialty Pharma 2,134 2,233 5% CDMO 1,024 1,148 12% 98 106 378 341 256 289 Generics 786 850 8% Reported EBITDA 1,087 1,127 4% India North Europe & ROW Adjust
Slide 17: LSI Segment Highlights – 9M'FY20
LSI Segment Highlights – 9M’FY20 Particulars 1 9M'FY19 9M'FY20 % Change LSI revenue at Rs 2,356 Crore, decrease of 11% YoY Revenue 2,633 2,356 (11%) Specialty Intermediates Specialty Intermediates 683 831 22% • Revenue increase of 22% YoY led by strong demand and better prices in Nutritional Produ
Slide 18: Drug Discovery & Development Solutions – 9M'FY20
Drug Discovery & Development Solutions – 9M’FY20 1 Particulars 9M'FY19 9M'FY20 % Change DDDS segment revenue increased 18% YoY to Rs 176 Crore led Revenue 149 176 18% by growth in Drug Discovery Services business, which was Drug Discovery Services 149 176 18% Proprietary Drug Discovery 0 0 - drive
Slide 19: Debt Profile
Debt Profile Particulars 31/03/19 30/09/19 30/12/19 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Subsidiaries 500 500 400 Total 500 500 400 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,341 1,029 1,156 Subsidiaries 61 21 37 Total 1,402 1,050 1,193 Gross Debt (Rs. Crs) (Rs. Crs) (Rs. Crs) Sta
Slide 20: Appendix
wW Mirescncts Appendix 19
Slide 21: Income Statement – Q3 & 9M'FY20
Income Statement – Q3 & 9M’FY20 1 Particulars Q3'FY19 Q3'FY20 YoY Growth 9M'FY19 9M'FY20 YoY Growth Total Revenue from Operations 2,377 2,315 (3%) 6725 6,763 1% Pharmaceuticals 1,424 1,450 2% 3943 4,231 7% Life Science Ingredients 899 797 (11%) 2633 2,356 (11%) Drug Discovery & Development Solutions
Slide 22: For more information
For more information For Investors: Ravi Agrawal/Vineet V Mayer Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 / 1021 Ph: +91 22 6645 1209 E-mail: ravi.Agrawal@jubl.com E-mail: siddharth@cdr-india.com Vineet.mayer@jubl.com For Media: Gaurav Kashyap Sudhakar Safaya